Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01809574
Recruitment Status : Unknown
Verified October 2013 by Meir Medical Center.
Recruitment status was:  Recruiting
First Posted : March 12, 2013
Last Update Posted : April 9, 2015
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center

Tracking Information
First Submitted Date March 10, 2013
First Posted Date March 12, 2013
Last Update Posted Date April 9, 2015
Study Start Date May 2013
Estimated Primary Completion Date March 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: March 11, 2013)
The number of patients with collagen related pulmonary fibrosis that are diagnosed by Rheumatologists compared to Pulmonologists. [ Time Frame: two years ]
Original Primary Outcome Measures Same as current
Change History Complete list of historical versions of study NCT01809574 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease
Official Title The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease
Brief Summary We hypothesized that the multi-disciplinary assessment of interstitial lung disease patients would lead to a more accurate diagnosis and consequently alterations in treatment regimens that may lead to improved outcomes.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population 60 patients that will refer to the pulmonary outpatient or inpatients department for evaluation due to ILD will be included
Condition
  • Interstitial Lung Disease
  • Idiopathic Pulmonary Fibrosis
  • Connective Tissue Disease
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: March 11, 2013)
60
Original Estimated Enrollment Same as current
Estimated Study Completion Date March 2016
Estimated Primary Completion Date March 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Age above 18 years old
  • ILD according to ATS/ERS guidelines
  • Signed inform consent

Exclusion Criteria:

  • Previous lung surgery
  • Other significant systemic disease
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Israel
Removed Location Countries  
 
Administrative Information
NCT Number NCT01809574
Other Study ID Numbers 225-12-MMC
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Meir Medical Center
Study Sponsor Meir Medical Center
Collaborators Not Provided
Investigators
Principal Investigator: David Shitrit, Dr Head of Pulmonary departmant, Meir Medical Center.
PRS Account Meir Medical Center
Verification Date October 2013